Bromocriptine

In healthy young adults given bromocriptine in a placebo-controlled crossover design, functional MRI showed that bromocriptine modulated task-related cortical activity depending on working memory capacity, with evidence for both task-specific enhancement and task-general inhibition of neural activity, highlighting individualized cognitive and neural responses to dopaminergic stimulation.

This placebo-controlled study in healthy young adults found that bromocriptine’s effects on cognitive performance were moderated by baseline working memory capacity, improving some aspects of performance in low-capacity individuals while impairing or not improving performance in high-capacity individuals, consistent with an inverted-U relationship for dopamine and cognition.

This review summarizes human trials of quick‑release bromocriptine given within 2 hours of waking, including a small study in 12 nondiabetic obese hyperinsulinemic adults where 1.6 mg/day for 2 weeks reduced fasting and postprandial glucose and halved insulin levels, and larger randomized trials in type 2 diabetes showing HbA1c reductions of about 0.5–0.7% without weight gain.

This review summarizes human trials of quick‑release bromocriptine given within 2 hours of waking, including a small study in 12 nondiabetic obese hyperinsulinemic adults where 1.6 mg/day for 2 weeks reduced fasting and postprandial glucose and halved insulin levels, and larger randomized trials in type 2 diabetes showing HbA1c reductions of about 0.5–0.7% without weight gain.

This review summarizes human trials of quick‑release bromocriptine given within 2 hours of waking, including a small study in 12 nondiabetic obese hyperinsulinemic adults where 1.6 mg/day for 2 weeks reduced fasting and postprandial glucose and halved insulin levels, and larger randomized trials in type 2 diabetes showing HbA1c reductions of about 0.5–0.7% without weight gain.

In a randomized, double-blind, placebo-controlled trial in 20 healthy young men, a single 5 mg oral dose of bromocriptine did not change resting mean arterial pressure, heart rate, or forearm blood flow but reduced central venous pressure and impaired reflex vasoconstriction during nitroprusside infusion and lower body negative pressure, suggesting peripheral inhibition of sympathetic neurotransmitter release without altering central sympathetic outflow.

In a randomized, double-blind, placebo-controlled trial in 20 healthy young men, a single 5 mg oral dose of bromocriptine did not change resting mean arterial pressure, heart rate, or forearm blood flow but reduced central venous pressure and impaired reflex vasoconstriction during nitroprusside infusion and lower body negative pressure, suggesting peripheral inhibition of sympathetic neurotransmitter release without altering central sympathetic outflow.